Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
OwnerJian-xing Mainventor
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a method of inhibiting at least one of vascular leakage, angiogenesis, inflammation and fibrosis in an animal by administering to the animal an effective amount of a composition, wherein the composition is selected from the group consisting of kallistatin, fragments of kallistatin, analogs or derivatives of kallistatin, and combinations thereof.
Claims23
A method of inhibiting vascular leakage in an animal who is not exhibiting pathological angiogenesis, comprising the step of:
- administering to an animal in need thereof an effective amount of a composition capable of inhibiting vascular leakage, wherein the composition comprises kallistatin, and wherein the effective amount of the composition is insufficient to inhibit pathological angiogenesis.
A method of inhibiting vascular leakage prior to onset of pathological angiogenesis, the method comprising the step of:
- administering to an animal in need thereof an effective amount of a composition capable of inhibiting vascular leakage prior to onset of pathological angiogenesis, wherein the composition comprises recombinantly-produced kallistatin, and wherein the effective amount of the composition is insufficient to inhibit pathological angiogenesis.
A method of inhibiting fibrosis in an animal who is not exhibiting pathological angiogenesis, comprising the step of:
- administering to an animal in need thereof an effective amount of a composition capable of inhibiting fibrosis, wherein the composition comprises kallistatin, and wherein the effective amount of the composition is insufficient to inhibit pathological angiogenesis.
A method of inhibiting inflammation in an animal who is not exhibiting pathological angiogenesis, comprising the step of:
- administering to an animal in need thereof an effective amount of a composition capable of inhibiting inflammation, wherein the composition comprises kallistatin, and wherein the effective amount of the composition is insufficient to inhibit pathological angiogenesis.
Dependencies are inferred from the claim text.